DTIL icon

Precision BioSciences

4.69 USD
+0.20
4.45%
At close Apr 2, 4:00 PM EDT
1 day
4.45%
5 days
0.64%
1 month
-6.20%
3 months
0.00%
6 months
-48.74%
Year to date
0.00%
1 year
-66.97%
5 years
-97.18%
10 years
-99.10%
 

About: Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Employees: 108

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 9

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

10% more funds holding

Funds holding: 51 [Q3] → 56 (+5) [Q4]

4.61% more ownership

Funds ownership: 45.97% [Q3] → 50.58% (+4.61%) [Q4]

51% less capital invested

Capital invested by funds: $29.8M [Q3] → $14.7M (-$15.1M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$34
625%
upside
Avg. target
$47
902%
upside
High target
$60
1,179%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
20% 1-year accuracy
10 / 51 met price target
1,179%upside
$60
Buy
Reiterated
28 Mar 2025
BMO Capital
Kostas Biliouris
6% 1-year accuracy
1 / 17 met price target
625%upside
$34
Outperform
Upgraded
10 Jan 2025

Financial journalist opinion

Based on 8 articles about DTIL published over the past 30 days

Neutral
Business Wire
1 day ago
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference taking place on April 7, 2025. Presentation Details: Date: Monday, April 7, 2025 Time: 3:00 PM ET in Track 2 Format: Pres.
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Negative
Zacks Investment Research
1 week ago
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $3.20 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $3.35 per share a year ago.
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates
Neutral
Business Wire
1 week ago
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2024, and provided a business update. “2024 was a transformational year for Precision BioSciences as we solidified ourselves as a leading in vivo gene editing company, and we.
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
Neutral
Business Wire
1 week ago
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical.
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
Neutral
Business Wire
1 week ago
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet diseases, presents preclinical data supporting repeat dosing of PBGENE-HBV in the ELIMINATE-B trial to treat patients with chronic HBV. Even with today's standard of care, an estimated 15% to 40% of patients with HBV infections may develop complications, such as cirrhosis, liver f.
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
Neutral
Business Wire
2 weeks ago
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including novel gene excision programs for high unmet need genetic diseases, today announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of Duchenne muscular dystrophy (DMD) during an oral presentation at the 2025 Muscular Dystrophy Association.
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Neutral
Business Wire
2 weeks ago
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PBGENE-HBV. PBGENE-HBV is Precision's lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating c.
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
Neutral
Business Wire
3 weeks ago
iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting
PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that initial data from the Phase 1/2 OTC-HOPE clinical trial evaluating in vivo gene editing candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency will be presented at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual.
iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting
Neutral
Business Wire
1 month ago
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that the company will present preclinical data from the PBGENE-DMD program for the treatment of Duchenne muscular dystrophy (DMD) during an oral presentation at the 2025 Muscular Dystrophy Association (MDA).
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Positive
Benzinga
1 month ago
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
On Wednesday, Precision BioSciences, Inc. DTIL revealed initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Charts implemented using Lightweight Charts™